Anti-IgE Significantly Changes Circulating Interleukin-25, Vitamin-D and Interleukin- 33 Levels in Patients with Allergic Asthma
Multi-center, randomized-controlled trials and observational studies have demonstrated that, in severe asthmatic patients receiving omalizumab treatment, the frequency of exacerbations, the number of urgent adverse events, and the need for oral steroids tend to decrease. To the best of our knowledge, this is the first study to compare circulating IL-25 and IL-33 levels with vitamin D synthesis in the literature. This study included a total of 32 patients. Serum IL-25 and IL-33 levels were measured and the number of emergency admissions, length of hospitalization (day), 25(OH)D, Asthma Control Test (ACT) scores, eosinophil cationic protein (ECP), and fractional exhaled nitric oxide (FeNO) value were analyzed. Correlation analysis revealed a moderate, positive, and significant relationship between the changes in the eosinophil counts and IL-33 levels (r=0.43, p=0.01). We found a weak, negative, and significant relationship between the changes in the ACT scores and IL-33 levels. In addition, there was a significant relationship between the changes in serum IL-33 levels and changes in the mite specific IgE levels and length of hospital stay with significantly higher coefficients.